Who does Pacira BioSciences, Inc. serve among hospitals and surgical pain specialists?
Pacira BioSciences, Inc. targets hospitals, ambulatory surgical centers, and anesthesiologists focused on non-opioid pain management; this audience matters as perioperative care shifts away from opioids. In 2025, expanded adoption of liposomal bupivacaine drove global OR penetration gains.
Buyers favor products lowering opioid use and length of stay; evidence-based hospital formularies and bundled-pay pilots boosted adoption in 2025. See product positioning in Pacira SWOT Analysis.
Who Is Pacira Really Trying to Reach?
Pacira BioSciences, Inc. targets healthcare institutions that purchase perioperative analgesia and clinicians who choose pain protocols; patients include surgical cases needing long – acting local analgesia and adults with knee osteoarthritis.
Main customer group: Hospitals and ASCs
Hospitals and ambulatory surgical centers buy EXPAREL and ZILRETTA for perioperative and osteoarthritis pain care, driving procurement and volume. These Pacira customers control formularies and purchasing decisions tied to procedure throughput.
Secondary customer groups: Clinicians and payers
Surgeons and anesthesiologists influence clinical adoption; payers and hospital pharmacy committees shape reimbursement and long – term uptake in the Pacira target market.
Customer type and market role
Pacira primarily serves institutions (B2B) while engaging clinicians (B2B2C) and supporting patient access; revenue flows from institutional sales with downstream patient benefit.
Most important segment: High – volume surgical specialties
Orthopedics (total knee arthroplasty, spinal fusion) and women's health (cesarean delivery, mastectomy) account for the largest usage and reimbursement opportunity; these drive >50% of perioperative EXPAREL utilization in hospital settings.
Core reach: Institutions plus clinician influencers
Pacira focuses on hospitals and surgical centers as the economic buyers while targeting surgeons and anesthesiologists as clinical decision makers; patient cohorts include surgical patients needing non – opioid analgesia and adults with knee osteoarthritis.
- Hospitals and ambulatory surgical centers are the primary Pacira customers
- Surgeons and anesthesiologists are the key clinical influencers
- Primarily a B2B model with clinician and patient-facing elements
- High – volume orthopedics and women's health procedures are the most commercially important segments
For historical context on market positioning and product evolution, see History of Pacira Company Explained
Pacira SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Do Pacira's Customers Care About?
Pacira customers care about lowering total cost of care, speeding patient throughput, and reducing opioid use while maintaining surgical outcomes; institutional buyers focus on hospital LOS and 30 – day costs, clinicians focus on opioid-sparing efficacy, and outpatient providers needed reimbursement parity to adopt high-cost non – opioid options.
Reducing length of stay and total costs
Hospitals and surgical centers want therapies that shorten stays and cut 30-day total costs; real-world data through March 2026 shows EXPAREL associated with a 1.83 – day shorter LOS in spinal fusion cases and materially lower 30 – day costs.
Practical buying drivers: reimbursement and throughput
Decision makers weigh total cost of care, patient throughput, and clear reimbursement; the NOPAIN Act plus J-code J0666 (effective January 1, 2025) enables separate Medicare payment to ASCs and HOPDs, making adoption viable.
Emotional appeal: patient safety and clinician confidence
Clinicians and patients value reduced opioid reliance to avoid addiction and complications; clinicians gain confidence using non-opioid options that demonstrably lower opioid needs post-op.
What customers value most: measurable outcomes
Buyers prioritize therapies with quantifiable impact on LOS, opioid use, and 30 – day cost metrics; published real-world evidence through March 2026 drives procurement decisions.
Loyalty drivers: reimbursement, data, and training
Repeat use follows when payers reimburse, clinicians see consistent outcomes, and the company provides clinical training and support for anesthesiologists and surgeons in hospitals and ambulatory surgery centers.
Why providers choose Pacira
Providers choose Pacira for non-opioid pain management backed by real-world outcome data, new Medicare reimbursement (J0666), and support for ASCs and HOPDs to reduce total cost of care.
What Those Customers Care About
Pacira target market-hospitals and surgical centers, anesthesiologists and surgeons, and patients needing non – opioid pain management-prioritize shorter LOS, lower 30 – day total costs, and opioid-sparing outcomes; reimbursement reforms (NOPAIN Act and J0666) removed the main financial barrier for ASCs and HOPDs.
- Shorter hospital length of stay and lower 30 – day total costs
- Separate Medicare reimbursement (J0666) enabling ASC/HOPD adoption
- Reduced opioid reliance for patient safety and fewer post-surgical complications
- Evidence – backed outcomes and payer support drive provider choice
For more context on company positioning and mission see What Pacira Company Stands For
Pacira PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Where Is Demand Strongest for Pacira?
Demand for Pacira BioSciences, Inc. products is strongest in North America, especially the U.S., where non – opioid pain treatment adoption is highest and outpatient shifting boosts volumes; ASCs and HOPDs are the fastest-growing care settings.
Primary market: U.S. outpatient settings
North America leads global demand; analysts project the region to hold 39.4 percent of the global non – opioid pain market in 2026, and U.S. growth is migrating from inpatient hospitals into ambulatory surgery centers (ASCs) and hospital – owned outpatient departments (HOPDs).
Secondary markets: hospitals and international expansion
Traditional hospitals remain meaningful buyers but face slower growth; Pacira is expanding in Asia – Pacific via a commercialization partnership with LG Chem and regulatory filings in South Korea and Thailand to access new patient pools.
Where Pacira is strongest
Pacira customers include anesthesiologists and surgeons at ASCs and hospitals who use EXPAREL for regional and local analgesia; the company shows strongest reach in ambulatory surgical centers where EXPAREL competes on efficacy and reimbursement.
Where demand is rising fastest (2025-2026)
ASC adoption is accelerating after CMS announced the 2026 phaseout of the inpatient – only list, moving more procedures to outpatient settings and increasing demand for non – opioid options like EXPAREL among patients needing non – opioid pain management.
Where Demand Is Strongest
North America-especially U.S. ASCs and HOPDs-concentrates demand; hospitals remain buyers, and Asia – Pacific expansion via LG Chem targets near – term growth in South Korea and Thailand.
- North America (U.S. outpatient shift; 39.4 percent market share in 2026)
- Hospitals and surgical centers remain core buyers
- Pacira strongest in ASCs and among anesthesiologists and surgeons
- Fastest growth: ASCs/HOPDs post – 2026 inpatient – only phaseout and Asia – Pacific rollout
Who Pacira Company Competes With
Pacira SOAR Analysis
- Complete SOAR Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
How Does Pacira Keep Its Audience Growing?
Pacira BioSciences, Inc. grows its audience by expanding payer coverage, scaling distribution partnerships, and moving into adjacent regenerative-health markets to reach more providers and patients.
Coverage and Distribution Expansion
Massive coverage wins pushed lives covered to 102 million by end – 2025 outside the surgical bundle, and the J&J MedTech partnership tripled U.S. reach for ZILRETTA, adding hospitals and surgical centers and anesthesiologists and surgeons.
Customer Retention Drivers
Clinical efficacy, payer alignment, and integrated training keep Pacira customers using products; payer and insurer engagement reduces friction for repeat use in ambulatory surgery centers and pain management clinics.
Loyalty, Repeat Demand, or Customer Depth
High clinical switching costs and ecosystem stickiness-clinical training for surgical teams, product familiarity among anesthesiologists, and hospital purchasing patterns-drive repeat demand for Exparel and ZILRETTA.
Strongest Growth Lever in 2025/2026
The 5x30 strategy-targeting >3 million patients annually by 2030-paired with payer coverage expansion (102 million lives) and partnership distribution is the main growth engine into 2026 when revenue is projected at $745-$770 million.
How It Keeps the Audience Growing
Pacira converts regulatory and payer tailwinds into clinical adoption, then scales reach via partnerships and new product categories like PCRX – 201 gene therapy for knee OA (addressable U.S. population > 14 million), expanding Pacira target market and deepening ties with Pacira healthcare providers.
- Primary growth driver: payer coverage expansion to 102 million lives
- Strongest retention factor: clinician training and demonstrated non – opioid efficacy
- Key loyalty mechanism: partner distribution (J&J MedTech) and hospital purchasing patterns
- Main risk: slower-than – expected clinical or regulatory progress for PCRX – 201 or reimbursement reversals
Pacira VRIO Analysis
- Covers VRIO Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
Frequently Asked Questions
Pacira's main customers are hospitals and ambulatory surgical centers. These institutions buy EXPAREL and ZILRETTA for perioperative and osteoarthritis pain care. The article also notes that surgeons, anesthesiologists, payers, and hospital pharmacy committees influence adoption, reimbursement, and long-term use.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.